Cohance Lifesciences is deploying $18 million of its own cash to increase its stake in NJ Bio to 67.3% and acquire 65% of Aruka Bio. The deal targets growth in the complex antibody-drug conjugate sector, though investors are also tracking recent leadership changes and regulatory observations at its manufacturing sites.
Cohance Lifesciences has announced an $18 million capital investment to strengthen its presence in the specialized antibody-drug conjugate (ADC) market. The company, formerly known as Suven Pharmaceuticals, plans to use its internal cash reserves to fund two strategic transactions. It will inject $13 million into NJ Bio to raise its equity stake to 67.3% and commit $5 million to acquire a 65% controlling interest in Aruka Bio. The deals are expected to be finalized by the end of September 2026.
Strategic Expansion into ADC
The move is designed to integrate the specialized services of NJ Bio and the advanced ADC technologies of Aruka Bio into the broader contract research, development, and manufacturing organization (CRDMO) platform of Cohance. ADC therapies represent a complex and high-value segment in drug development, where biological antibodies are paired with drugs to target specific diseases. By consolidating these entities, management aims to offer a more unified service to global pharmaceutical clients.
Because the company is funding these acquisitions entirely through internal cash reserves rather than debt, it avoids increasing its financial leverage. However, investors are observing the broader operational context, as the company faces a period of transition and scrutiny.
Financial and Regulatory Context
The business is currently navigating a challenging financial phase. For the quarter ended June 30, 2026, the company reported a consolidated net loss of ₹24.12 crore, reflecting volatility in its recent revenue performance. Shareholders are also monitoring regulatory developments, as the company has received a warning letter from the USFDA regarding its Nacharam formulation facility. Additionally, an August 2026 inspection of its Pashamylaram facility resulted in five observations from the regulator. Resolving these compliance matters remains an important operational priority for the management team.
Leadership Transition
The company is also undergoing significant leadership changes. Umang Vohra took over as the new Executive Chairman and Group CEO in May 2026. Furthermore, the company’s Chief Financial Officer is set to resign in mid-September 2026. These management transitions, coupled with the ongoing integration of new business units and the need to address facility-related regulatory observations, form the primary areas for investor monitoring in the coming quarters. The successful execution of the ADC business integration will be a key factor in how the company attempts to improve its financial and operational standing.